# Efficacy and Safety of Curosurf® in Patients Invasively Ventilated for Severe Bronchiolitis Under 12 Months of Age

> **NCT03959384** · PHASE3 · TERMINATED · sponsor: **Azienda Ospedaliera Universitaria Integrata Verona** · enrollment: 9 (actual)

## Conditions studied

- Bronchiolitis, Viral

## Interventions

- **DRUG:** Curosurf 80Mg/Ml Intratracheal Suspension
- **OTHER:** Ambient Air

## Key facts

- **NCT ID:** NCT03959384
- **Lead sponsor:** Azienda Ospedaliera Universitaria Integrata Verona
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-01-09
- **Primary completion:** 2021-04-09
- **Final completion:** 2021-04-09
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Due to COVID19 hospital admissions by patients with moderate-severe bronchiolitis have drastically decreased from 02/2020 to date. Moreover, many centers that had initially joined the study project had great difficulties in the activation phase
- **Last updated:** 2021-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03959384

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03959384, "Efficacy and Safety of Curosurf® in Patients Invasively Ventilated for Severe Bronchiolitis Under 12 Months of Age". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT03959384. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*